Señales en vivo de EQRX | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 nov 2023 @ 16:00):

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States...

Stats
Volumen de hoy	11.93M
Volumen promedio	2.95M
Capitalización de mercado	1.14B
EPS	$-0.180 ( 2023-11-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.25
ATR14	$0.0660 (2.82%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-09	Casdin Eli	Sell	5 488 164	Common Stock
2023-11-09	Casdin Eli	Sell	8 110 001	Warrants to purchase Class A Common Stock (right to buy)
2023-11-09	Casdin Eli	Sell	755 766	Earn-out Shares
2023-11-09	Casdin Eli	Sell	101 010	Stock Option (Right to Buy)
2023-11-09	Nallicheri Melanie	Buy	626 999	Common Stock

INSIDER POWER
-96.21
Last 94 transactions
Buy: 76 186 838 \| Sell: 93 441 879

Volumen Correlación

Largo: 0.04 (neutral)

Corto: -0.25 (neutral)

Signal:(55.606) Neutral

EQRx, Inc. Correlación

10 Correlaciones Más Positivas
BSRR	0.931
MPAA	0.931
CLGN	0.931
ENG	0.929
CPTN	0.927
VBTX	0.926
MYFW	0.926
UBFO	0.925
SFNC	0.924
BPYPN	0.924

10 Correlaciones Más Negativas
RMBS	-0.899
LYTS	-0.898
CCRC	-0.895
KE	-0.894
ISDX	-0.893
JMPNZ	-0.893
PPYAU	-0.892
IEUS	-0.891
LRFC	-0.89
HEWG	-0.89

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

EQRx, Inc. Correlación - Moneda/Commodity

-0.05
( neutral )

0.32
( neutral )

0.00
( neutral )

-0.58
( weak negative )

-0.47
( neutral )

0.77
( moderate )

EQRx, Inc. Finanzas

Annual	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$0.430

FY	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$0.430

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.205

FY	2020
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.513

Financial Reports:

No articles found.

EQRx, Inc.

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.